Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
A development race for immune checkpoint inhibitors is heating up between five camps of drug makers - Bristol-Myers Squibb (BMS)/Ono Pharmaceutical, US Merck & Co., AstraZeneca, Roche, and German Merck KGaA/Pfizer. Each camp released a series of trial results during…
To read the full story
Related Article
- ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured
September 1, 2015
- ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
- ASCO Immunotherapy Roundup - 7: Patient Group Hails Dawn of New Cancer Treatment Era
August 14, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- ASCO Immunotherapy Roundup - 4: Merck KGaA Trailing Rivals with ADCC-Inducing Avelumab
July 30, 2015
- ASCO Immunotherapy Roundup - 3: AZ Set to Harness Rich Pipeline to Pursue Combo Strategy
July 16, 2015
- ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
BUSINESS
- Japan’s 1st Xolair Biosimilar Finally Set for December Launch after Delays
October 23, 2026
- PHP Security Flaws Trigger Website Shutdowns Across Japan Pharma Sector
October 23, 2026
- Enhertu Snares China Approval for HER2 Positive Solid Tumors
October 23, 2026
- Nxera Seeks South Korean Approval for DMD Drug Vamorolone
October 23, 2026
- Vital KSK Warns of Possible Email Address Leak via External Mail Provider
October 23, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…